Graphical Abstract: Cell-free production of personalized therapeutic phages targeting multidrug-resistant bacteria
CREDIT: Barth van Rossum / Clarafi
Cell-free production of bacteriophages
The World Health Organization (WHO) regards multi-resistant germs as among the largest threats to health. In the European Union alone, 33,000 people die each year as the result of bacterial infections which cannot be treated with antibiotics. Alternative treatments or drugs are therefore urgently needed.
Bacteriophages, the natural enemies of bacteria, are one promising solution. There are millions of different types of these viruses on earth, each of which specializes in certain bacteria. In nature, the viruses use the bacteria to reproduce; they insert their DNA into the bacteria, where the viruses quickly multiply. Ultimately they kill off the cell and move on to infect new cells. Bacteriophages work as a specific antibiotic by attacking and destroying a particular type of bacterium.
Viruses for health
“Bacteriophages offer an enormous potential for the highly effective, personalized therapy of infectious bacterial diseases,” observes Gil Westmeyer, Professor of Neurobiological Engineering at the Technical University of Munich (TUM) and Director of the Institute for Synthetic Biomedicine at Helmholtz Munich. “However, in the past, it wasn’t possible to produce bacteriophages in a targeted, reproducible, safe and efficient manner – although these are exactly the decisive criteria for the successful production of pharmaceuticals.”
Now the research team has developed a new controlled production method to create bacteriophages for therapeutic use. The basis for this technology was established by a group of students at TUM and Ludwig Maximilian University of Munich (LMU), who earned an award in the 2018 International Genetically Engineered Machine competition (iGEM). This group then gave rise to the start-up Invitris, which is currently developing a platform technology for phage-based medications.
The cornerstone of the new technology, which is already in the patent application process and is now being used in new research at TUM, is a special nutrient solution in which the bacteriophages form and reproduce. The nutrient solution consists of an E. coli extract and contains no viable cells; this is a fundamental difference from previous bacteriophage production methods, which traditionally used cell cultures with potentially infectious strains of bacteria.
In the TUM labs, the Munich team has now been able to demonstrate targeted production of bacteriophages in the cell-free nutrient solution: The only component needed is the genome – the plain DNA – of the desired viruses. The genome contains the entire blueprint for the formation of the bacteriophages. When the DNA is injected into the nutrient solution containing the molecular components and enzymes of the E. coli bacterium, the proteins assemble according to the blueprint: Thousands of identical copies are generated in just a few seconds. “This production method is not only fast and efficient, but it’s also very clean – the process eliminates contamination by bacterial toxins or other bacteriophages, which are a possible complications in cell cultures,” says Westmeyer.
But is the new cell-free nutrient solution actually suited for the production of bacteriophages that could be used in individual therapies? The researchers put the idea to the test together with the Bundeswehr Hospital Berlin: Using a bacterial sample from a patient who was suffering from an antibiotic-resistant skin infection, the Munich team screened for a promising, novel bacteriophage and isolated its DNA. The phage was then produced in the cell-free nutrient solution and finally used to successfully combat the multi-resistant bacteria.
A genetic archive for emergencies
“Our studies prove the feasibility of a cell-free method for producing effective bacteriophages for personalized medicine that can also be used to address multi-resistant germ infections,” says Westmeyer. He adds that in the future the methodology could ideally be used together with a genetic archive that would store the DNA of the relevant bacteriophages. Whenever necessary, this archive could be used to quickly produce complete bacteriophages in the nutrient solution, test their efficacy and then to apply the phages in the appropriate combinations, Westmeyer says, adding that although this work is still at the basic research stage, the method nevertheless has potential for clinical trials.
Original Article: Viruses help combat antibiotic-resistant bacteria
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Global Bacteriophages Therapy Market Size Is Expected To Grow At A CAGR Of Approx. 5% From 2022 To 2032
Evolve Business Intelligence published a new market research report on Global Bacteriophages Therapy Market By Targeted Bacteria (Escherichia coli, Staphylococcus aureus, Streptococcus ...
- A surprising precision weapon against Crohn’s and ulcerative coli
Weizmann Institute of Science researchers found a way to kill inflammation-causing bacteria in the gut that causes inflammatory bowel disease by using viruses that infect them.
- Novel Insights into Jumbo Phages and Their Defenses against Bacteria
A group of researchers report new insights into previously unrecognized phage biological structures and processes.
- Bacteriophage Market Growth and Restrain Factors Analysis [ 2021 – 2031 ]
Bacteriophages, or phages, refer to viruses that selectively target and exclusively kill bacteria. These phases are considered one of the most widespread biological entities that have an ability ...
- Bacteriophages Displaying Anticancer Peptides in Combined Antibacterial and Anticancer Treatment
Andrzej Górski Anticancer activity of YIGSR-presenting bacteriophages (YIGSR phage) was investigated in vivo in a model of tumor surgery-related infection accompanied by a tumor recurrence.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Killing bacteria with viruses
- iNtRON developed New CRISPR/Cas technology specific for Bacteriophage as PHAGERUS® Platform
CRISPR/Cas system for bacteria that are not E. coli or Streptococcus pyogenes Customized gene editing technology for unique modified-bacteriophages To validate efficacy of SARS-CoV-2 mimotopes loaded ...
- Phage Therapy Starts Realizing Its Long-Deferred Potential
Soon after bacteria-killing viruses were independently discovered by English physician Frederick Twort in 1915 and by French microbiologist Felix d’Herelle in 1917, the tiny microbes were seen to have ...
- Giant viruses beat diseases with their Aztec-like shield
Researchers from the University of California San Diego claim that a virus strain called bacteriophages could be able to kill dangerous bacteria.
- Israeli scientists developing ‘precision’ viruses that kill bowel-harming bacteria
In peer-reviewed study, Weizmann researchers tout ‘silver bullet’ approach promising pinpointed suppression of disease-causing microbes in Crohn’s and ulcerative colitis patients ...
- E. coli that is recoded to be virus resistant may aid drug production
Changing Escherichia coli's genetic code may enable the recoded bacterium to be grown in large vats for drug production, without the risk of a viral infection upending the process ...